Your browser is no longer supported. Please, upgrade your browser.
ZYNE Zynerba Pharmaceuticals, Inc. monthly Stock Chart
ZYNE [NASD]
Zynerba Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.89 Insider Own13.78% Shs Outstand23.13M Perf Week-32.24%
Market Cap191.05M Forward P/E- EPS next Y-1.97 Insider Trans0.00% Shs Float20.29M Perf Month-30.59%
Income-35.90M PEG- EPS next Q-0.52 Inst Own38.50% Short Float24.56% Perf Quarter-38.08%
Sales0.09M P/S2221.56 EPS this Y-5.20% Inst Trans237.05% Short Ratio4.15 Perf Half Y42.91%
Book/sh3.87 P/B2.13 EPS next Y3.00% ROA-46.10% Target Price21.75 Perf Year5.09%
Cash/sh3.83 P/C2.15 EPS next 5Y- ROE-52.20% 52W Range2.75 - 16.47 Perf YTD178.11%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-49.85% Beta4.81
Dividend %- Quick Ratio9.40 Sales past 5Y- Gross Margin- 52W Low200.36% ATR0.90
Employees25 Current Ratio9.40 Sales Q/Q- Oper. Margin- RSI (14)27.56 Volatility13.81% 8.14%
OptionableYes Debt/Eq0.00 EPS Q/Q43.40% Profit Margin- Rel Volume1.19 Prev Close8.45
ShortableYes LT Debt/Eq0.00 EarningsAug 15 BMO Payout- Avg Volume1.20M Price8.26
Recom1.80 SMA20-25.20% SMA50-26.74% SMA200-6.39% Volume1,434,279 Change-2.25%
Apr-22-19Resumed Canaccord Genuity Buy
Feb-01-18Resumed H.C. Wainwright Buy $23
Jan-29-18Initiated Ladenburg Thalmann Buy $25.50
Jan-26-18Initiated Seaport Global Securities Buy $16
Oct-02-17Upgrade Cantor Fitzgerald Neutral → Overweight $4 → $17
Sep-29-17Upgrade Piper Jaffray Neutral → Overweight
Aug-15-17Upgrade ROTH Capital Neutral → Buy
Aug-15-17Downgrade Oppenheimer Outperform → Perform
Aug-15-17Downgrade Jefferies Buy → Hold
Aug-08-17Downgrade ROTH Capital Buy → Neutral
Aug-08-17Downgrade H.C. Wainwright Buy → Neutral $7
Aug-07-17Downgrade Piper Jaffray Overweight → Neutral
Aug-07-17Downgrade Maxim Group Buy → Hold
Aug-07-17Downgrade Cantor Fitzgerald Overweight → Neutral $28 → $4
Mar-28-17Reiterated H.C. Wainwright Buy $22 → $30
Feb-24-17Initiated Maxim Group Buy $32
Dec-22-16Initiated Cantor Fitzgerald Overweight $28
Dec-06-16Resumed Jefferies Buy
Oct-07-16Initiated H.C. Wainwright Buy $22
Nov-12-15Reiterated Oppenheimer Outperform $40 → $34
Sep-20-19 11:00AM  Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Zynerba Pharmaceuticals (ZYNE) ACCESSWIRE
Sep-19-19 05:16PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Zynerba Pharmaceuticals  ZYNE GlobeNewswire
10:29AM  Zynerba Releases Data on Epilepsy Candidate, Stock Down Zacks
Sep-18-19 09:34AM  Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE): A Fundamentally Attractive Investment Simply Wall St. -21.77%
09:30AM  Zynerba Plunges On Midstage Zygel Data In Epileptic Patients Benzinga
06:30AM  Zynerba Pharmaceuticals Announces Positive Top Line Data from BELIEVE 1 Open Label Phase 2 Study of Zygel in Developmental and Epileptic Encephalopathies (DEE) GlobeNewswire
Sep-17-19 05:01AM  Zynerba Stock is a Medical Cannabis Investment You Can Feel Good About InvestorPlace
Sep-11-19 10:47AM  14 Top Cannabis Stocks Targeted By Short Sellers Benzinga
Sep-03-19 11:30AM  Zynerba Pharmaceuticals to Present at Two Upcoming Conferences GlobeNewswire
Aug-31-19 06:13PM  Top Marijuana Stocks on the NASDAQ Investopedia
Aug-29-19 07:30AM  Zynerba Pharmaceuticals Announces Poster Presentations at the 22nd Society for the Study of Behavioural Phenotypes (SSBP) Symposium GlobeNewswire
Aug-18-19 07:37AM  3 Healthcare Stocks to Fight Off the Market Flu TipRanks
Aug-08-19 10:57AM  When Can We Expect A Profit From Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE)? Simply Wall St.
Aug-07-19 06:33PM  Here's Why Zynerba Pharmaceuticals Lost 21.8% in July Motley Fool +13.09%
Aug-06-19 09:40AM  Zynerba (ZYNE) Meets Earnings Estimates in Q2, Revenues Nil Zacks +5.31%
08:00AM  Zynerba Pharmaceuticals Announces Publication of Zygel (ZYN002) 12-week Open Label Fragile X Syndrome Data in the Journal of Neurodevelopmental Disorders GlobeNewswire
06:45AM  Zynerba Pharmaceuticals Reports Second Quarter 2019 Financial Results and Operational Highlights GlobeNewswire
Jul-31-19 08:00AM  Zynerba Pharmaceuticals to Present at Two Upcoming Conferences GlobeNewswire
Jul-24-19 09:00AM  What's in the Cards for Zynerba (ZYNE) This Earnings Season? Zacks
Jul-23-19 09:42AM  Zynerba Pharma Looks Like Bad Medicine for Investors TheStreet.com -8.72%
07:41AM  Jim Cramer Weighs In On Berkshire Hathaway, Range Resources, Zynerba And More Benzinga
Jul-18-19 05:45PM  Zynerba Pharmaceuticals (ZYNE) Outpaces Stock Market Gains: What You Should Know Zacks
Jul-12-19 04:26PM  Here's Why Zynerba Pharmaceuticals Stock Soared 356% in the First Half of the Year Motley Fool -5.28%
07:15AM  5 Best Biotech Stocks of 2019 So Far Motley Fool
Jul-11-19 05:50PM  Zynerba Pharmaceuticals (ZYNE) Outpaces Stock Market Gains: What You Should Know Zacks
Jul-03-19 08:31AM  These Are the Only 15 Pot Stocks That Rose in the Second Quarter Motley Fool
Jul-02-19 05:50PM  Zynerba Pharmaceuticals (ZYNE) Outpaces Stock Market Gains: What You Should Know Zacks
06:03AM  Is Zynerba Pharmaceuticals's (NASDAQ:ZYNE) 102% Share Price Increase Well Justified? Simply Wall St.
Jul-01-19 05:01PM  Why Medicare for all could 'dramatically' increase access to medical marijuana Yahoo Finance
08:21AM  The Best Marijuana Stocks in the First Half of 2019 Motley Fool
07:30AM  Zynerba Pharmaceuticals Added to Russell 2000® and 3000® Indexes GlobeNewswire
Jun-28-19 11:13AM  Canaccord Genuity Bullish On Zynerba Ahead Of CBD Gel Trial Data Benzinga +6.61%
Jun-26-19 05:45PM  Zynerba Pharmaceuticals (ZYNE) Dips More Than Broader Markets: What You Should Know Zacks
Jun-20-19 09:15AM  Fed Statement Keeps Rally Alive Zacks
Jun-19-19 05:45PM  Zynerba Pharmaceuticals (ZYNE) Outpaces Stock Market Gains: What You Should Know Zacks
Jun-13-19 07:04PM  Understanding Medical Cannabis vs. Recreational Cannabis Stocks Investopedia
03:11PM  MediaJel Acquires Potnt Agency, Adds Merida Capital's Thomas Harrison As Chairman Benzinga
Jun-12-19 05:45PM  Zynerba Pharmaceuticals (ZYNE) Gains As Market Dips: What You Should Know Zacks
09:39AM  Zynerba Up on Second Patent for Cannabidiol Candidate in 2019 Zacks
Jun-11-19 12:00PM  Why Zynerba Pharmaceuticals Stock Is Skyrocketing Today Motley Fool +16.58%
11:26AM  Zynerba Stock Soars on Cannabidiol Patent for Autism Spectrum Disorder InvestorPlace
08:22AM  Zynerba Advances Cannabidiol Treatment With New Patent Win Benzinga
07:00AM  Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Autism Spectrum Disorder with Cannabidiol GlobeNewswire
Jun-04-19 06:00AM  Here's What Last Week's FDA CBD Hearing Really Means for Cannabis Stocks Motley Fool +12.72%
May-31-19 09:40AM  Zynerba Initiates Phase II INSPIRE Trial Of Zygel Market Exclusive
May-30-19 04:30PM  Zynerba Pharmaceuticals to Present at FDAs Public Hearing on Scientific Data and Information about Products Containing Cannabis or Cannabis-derived Compounds GlobeNewswire
May-29-19 06:45AM  Zynerba Pharmaceuticals Announces Initiation of Phase 2 Trial of Zygel in 22q11.2 Deletion Syndrome GlobeNewswire +7.04%
May-28-19 11:30AM  Zynerba Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference GlobeNewswire -8.35%
10:43AM  3 Strong Buy Cannabis Biotech Stocks To Know Now TipRanks
May-24-19 09:30AM  Is Zynerba Pharmaceuticals (ZYNE) Outperforming Other Medical Stocks This Year? Zacks
08:32AM  UC Davis researcher looks to cannabis compound to treat developmental disorders American City Business Journals
May-23-19 08:41AM  Options Traders Expect Huge Moves in Zynerba Pharmaceuticals (ZYNE) Stock Zacks -7.71%
May-21-19 08:07AM  Zynerba Pharmaceuticals, Inc. (ZYNE) Shares March Higher, Can It Continue? Zacks
May-10-19 02:16PM  Can We See Significant Insider Ownership On The Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Share Register? Simply Wall St. +6.69%
May-08-19 09:30AM  Is Zynerba Pharmaceuticals (ZYNE) Outperforming Other Medical Stocks This Year? Zacks
06:58AM  Zynerba: 1Q Earnings Snapshot Associated Press
06:50AM  Zynerba Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights GlobeNewswire
May-06-19 04:20PM  Why Zynerba Pharmaceuticals Stock Zoomed Higher Today Motley Fool +11.44%
12:14PM  Zynerba stock soars after getting 'fast track' designation for experimental cannibanoid therapy American City Business Journals
07:00AM  Zynerba Pharmaceuticals Receives Fast Track Designation for Zygel for the Treatment of Behavioral Symptoms Associated with Fragile X Syndrome (FXS) GlobeNewswire
Apr-30-19 11:56AM  Why Zynerba Pharmaceuticals Stock Is Jumping Today Motley Fool +8.30%
10:02AM  What's in the Cards for Zynerba (ZYNE) This Earnings Season? Zacks
Apr-24-19 05:45PM  Zynerba Pharmaceuticals (ZYNE) Gains As Market Dips: What You Should Know Zacks
Apr-18-19 09:30AM  Is Zynerba Pharmaceuticals (ZYNE) Stock Outpacing Its Medical Peers This Year? Zacks
Apr-17-19 05:45PM  Zynerba Pharmaceuticals (ZYNE) Dips More Than Broader Markets: What You Should Know Zacks
Apr-16-19 12:28PM  5 Marijuana Stocks Wall Street Is Most Bullish On Kiplinger
Apr-15-19 05:55AM  Will Zynerba Pharmaceuticals Continue to Surge Higher? Zacks
Apr-11-19 02:35PM  These Four Marijuana Stocks Could Make Moves On Thursday ACCESSWIRE +8.15%
Apr-05-19 08:50AM  Is the Options Market Predicting a Spike in Zynerba Pharmaceuticals (ZYNE) Stock? Zacks +13.08%
Apr-02-19 03:52PM  Ladenburg Bullish on Zynerba (ZYNE) Stock as FDA Clarifies Its Views on Availability of Non-Prescription CBD SmarterAnalyst +20.00%
10:00AM  Zynerba Pharmaceuticals to Present at the 2019 H.C. Wainwright Global Life Sciences Conference GlobeNewswire
Mar-22-19 01:00PM  Cannabis Breakout Candidates - THC Therapeutics, Inc. (THCT) ACCESSWIRE -6.02%
09:27AM  Will Zynerba Pharmaceuticals Continue to Surge Higher? Zacks
Mar-20-19 01:45PM  These Four Marijuana Stocks Are Bringing The Heat On Wednesday ACCESSWIRE +11.67%
Mar-18-19 03:36PM  These 3 Cannabis Stocks Are Set to Skyrocket, Say Analysts SmarterAnalyst
Mar-14-19 04:39PM  SCYNEXIS Reports Full Year 2018 Financial Results and Provides Company Update PR Newswire
Mar-11-19 06:58AM  Zynerba: 4Q Earnings Snapshot Associated Press
06:50AM  Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2018 Financial Results and Operational Highlights GlobeNewswire
Mar-07-19 07:00AM  Zynerba Pharmaceuticals Initiates Phase 2 Trial of Zygel in Autism Spectrum Disorder GlobeNewswire
Mar-01-19 12:35PM  Does Zynerba Pharmaceuticals, Inc.s (NASDAQ:ZYNE) CEO Pay Reflect Performance? Simply Wall St.
Feb-26-19 10:21AM  Zynerba's Patent Win Sends Cannabis Biotech's Shares Higher Benzinga
09:45AM  These Four Healthcare Stocks Are Heating Up On Tuesday ACCESSWIRE
07:00AM  Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Fragile X Syndrome with Cannabidiol GlobeNewswire
Feb-21-19 01:26PM  Zynerba Pharmaceuticals Receives International Patent For Osteoarthritis Treatment With CBD Gel Benzinga +5.71%
Feb-20-19 07:00AM  Zynerba Pharmaceuticals Appoints Pamela Stephenson to Board of Directors GlobeNewswire
Feb-13-19 11:45AM  Healthcare Investment Opportunities You Can't Miss ACCESSWIRE
Feb-11-19 09:55AM  Biotech Stocks To Watch ACCESSWIRE
Feb-08-19 09:30AM  Has Zynerba Pharmaceuticals (ZYNE) Outpaced Other Medical Stocks This Year? Zacks
Feb-07-19 11:44AM  Zynerba Stock Is Marijuana-Adjacent Play Worth a Look InvestorPlace
Feb-05-19 10:00AM  Zynerba Pharmaceuticals to Present at the 2019 BIO CEO and Investor Conference GlobeNewswire -6.69%
Feb-04-19 03:41PM  Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q3 Zacks +5.87%
11:00AM  Cannabis & Biotech Stocks Starting to Rally in 2019 ACCESSWIRE
Feb-01-19 08:30AM  Biotechs to Put on Your Watchlist ACCESSWIRE +10.50%
Jan-30-19 08:00AM  Today's Research Reports on Trending Tickers: BioTime and Zynerba Pharmaceuticals ACCESSWIRE
08:00AM  Biotechs You Need to Radar Now ACCESSWIRE
Jan-29-19 02:30PM  These 4 Healthcare Stocks Healthy With Potential Opportunities ACCESSWIRE +25.26%
12:56PM  Zynerba Pharmaceuticals News: Why ZYNE Stock Is Soaring Today InvestorPlace
08:30AM  Wall Street's Favorite Cannabis Stock Benzinga
Jan-22-19 08:45AM  SCYNEXIS Announces Appointment of Industry Veteran Armando Anido to its Board of Directors PR Newswire
Jan-07-19 09:00AM  Options Traders Expect Huge Moves in Zynerba Pharmaceuticals (ZYNE) Stock Zacks
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. It focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company is developing Zygel, a transdermal cannabidiol gel, which is in Phase II clinical trial for treating children and adolescent patients with developmental and epileptic encephalopathies; is in Phase II/III clinical trial to treat children and adolescent patients with fragile X syndrome; and is in Phase II clinical trial for treating children and adolescent patients with autism spectrum disorder. It is also developing ZYN001, a pro-drug of tetrahydrocannabinol. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Devon, Pennsylvania.